AML, Carcinoma, Carcinoma Bladder, Carcinoma Breast, Carcinoma Cervix, Carcinoma, Ductal, Carcinoma, Hepatocellular, Carcinoma, Neuroendocrine, Carcinoma, Non-Small-Cell Lung, Carcinoma of Esophagus, Carcinoma of Lung, Carcinoma of the Anus, Carcinoma of the Appendix, Carcinoma of the Head and Neck, Carcinoma of the Larynx, Carcinoma of the Lip, Carcinoma of the Oral Cavity, Carcinoma of the Oropharynx, Carcinoma of the Paranasal Sinus, Carcinoma of the Penis, Carcinoma of the Skin, Carcinoma of the Vulva, Carcinoma of Unknown Primary, Carcinoma, Ovarian, Carcinoma, Pancreatic, Carcinoma Prostate, Carcinoma, Renal Cell, Carcinoma, Small Cell Lung, Carcinoma, Thymic, Cholangiocarcinoma, Malignant Ascites, Malignant Pleural Effusion, Mesothelioma, Multiple Myeloma in Relapse, Stage III Breast Cancer, Stage III Lung Cancer, Stage IV Breast Cancer, Stage IV Lung Cancer
Conditions
Brief summary
The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from varying cancers and biopsy formats.
Interventions
None listed
Sponsors
Travera Inc
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Sample collection or biopsy of tumor is clinically indicated as part of SOC * Prior to preceding onto therapy for treatment
Exclusion criteria
* Unable to obtain sufficient sample
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Best overall response (BOR) | up to 24 months | The best overall response to therapy over 24 months will be captured for correlation with test outcomes. |
Outcome results
None listed